Literature DB >> 16598780

Invasive aspergillosis in the recipients of liver retransplantation.

Nina Singh1, Timothy L Pruett, Sally Houston, Patricia Muñoz, Thomas V Cacciarelli, Marilyn M Wagener, Shahid Husain.   

Abstract

Retransplantation is a major risk factor for invasive aspergillosis in liver transplant recipients. However, the risk for invasive aspergillosis with time elapsed since retransplantation, clinical characteristics, and outcome of patients who develop this infection after retransplantation of the liver has not been defined. Patients comprised 17 liver retransplant recipients with invasive aspergillosis between 1990 and 2004. Retransplantation was considered early if it was performed within 30 days and late if performed after 30 days of the first or primary transplant. Retransplant recipients comprised 25% of all cases of invasive aspergillosis after liver transplantation. Fifty-three percent of the Aspergillus infections occurred within 30 days, and 76% within 90 days of retransplantation. In all, 53% (9/17) of the patients were late retransplant recipients. Late compared to early retransplant recipients with invasive aspergillosis were more likely to have central nervous system involvement with invasive aspergillosis (56% vs. 0%, P = 0.03). Mortality rate was 100% for late and 63% for early retransplant recipients with Aspergillus infections. In conclusion, time-varying risk for invasive aspergillosis after retransplantation has implications relevant for guiding antifungal prophylaxis. Given a greater risk for disseminated infection and poor outcome in late retransplant recipients with aspergillosis, potent and aggressive antifungal therapy should be considered upfront in these patients. (c) 2006 AASLD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16598780     DOI: 10.1002/lt.20756

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  9 in total

Review 1.  Neurologic complications after liver transplantation.

Authors:  Saša A Zivković
Journal:  World J Hepatol       Date:  2013-08-27

2.  Infections in liver transplant recipients.

Authors:  Fabian A Romero; Raymund R Razonable
Journal:  World J Hepatol       Date:  2011-04-27

Review 3.  Renal aspergillosis after liver transplantation: clinical and imaging manifestations in two cases.

Authors:  Xiao-Chun Meng; Ting Jiang; Shu-Hong Yi; Pei-Yi Xie; Yue-Fei Guo; Li Quan; Jing Zhou; Kang-Shun Zhu; Hong Shan
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

Review 4.  Invasive fungal infections in transplant recipients.

Authors:  Jose A Vazquez; Marisa H Miceli; George Alangaden
Journal:  Ther Adv Infect Dis       Date:  2013-06

5.  Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts?

Authors:  Rafael Zaragoza; Javier Pemán; Miguel Salavert; Angel Viudes; Amparo Solé; Isidro Jarque; Emilio Monte; Eva Romá; Emilia Cantón
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

Review 6.  Invasive fungal infections in solid organ transplant recipients.

Authors:  Shmuel Shoham; Kieren A Marr
Journal:  Future Microbiol       Date:  2012-05       Impact factor: 3.165

Review 7.  Infectious Complications Following Solid Organ Transplantation.

Authors:  Alexis Guenette; Shahid Husain
Journal:  Crit Care Clin       Date:  2019-01       Impact factor: 3.598

8.  Invasive aspergillosis in solid organ transplant patients: diagnosis, prophylaxis, treatment, and assessment of response.

Authors:  Dionysios Neofytos; Carolina Garcia-Vidal; Frédéric Lamoth; Christoph Lichtenstern; Alessandro Perrella; Jörg Janne Vehreschild
Journal:  BMC Infect Dis       Date:  2021-03-24       Impact factor: 3.090

9.  Fungal infections: their diagnosis and treatment in transplant recipients.

Authors:  David H Van Thiel; Magdalena George; Christopher M Moore
Journal:  Int J Hepatol       Date:  2012-08-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.